British Medical Bulletin Advance Access originally published online on November 23, 2008
British Medical Bulletin 2008 88(1):131-146; doi:10.1093/bmb/ldn042
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The relationship between type 2 diabetes and dementia




Metabolic Unit, Western General Hospital, Edinburgh, UK
Endocrinology Unit, Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK
¶ Department of Diabetes, Royal Infirmary of Edinburgh, Edinburgh, UK
Department of Public Health Sciences, University of Edinburgh, Edinburgh, UK
Correspondence to: Dr M. W. J. Strachan, Metabolic Unit, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK. E-mail: mark.strachan{at}luht.scot.nhs.uk
Introduction: The prevalence of type 2 diabetes and dementia are set to rise inexorably over the next 30–40 years. There are now substantial data to suggest that type 2 diabetes is associated with an increased risk of dementia.
Sources of data: This is a narrative review using data from individual studies and review articles known to the authors. A Medline search was also undertaken and reference lists were reviewed to identify additional relevant studies.
Areas of agreement: Type 2 diabetes is associated with an increased risk of both Alzheimer's and Vascular dementia, although the reality is that many affected individuals have mixed forms of dementia.
Areas of controversy: The mechanisms underpinning this association remain to be clearly delineated. Type 2 diabetes is a complex disorder and so it is likely that multiple different, synergistic processes may interact to promote cognitive decrements.
Growing points: Recent data suggest that glucocorticoids excess and elevated inflammatory markers may also have a role in the aetiology of diabetes-related cognitive impairment.
Areas timely for developing research: Large-scale, prospective epidemiological studies are now required to accurately delineate the pathogenesis of cognitive impairment in people with type 2 diabetes. These are underway and randomized trials of diabetes-specific interventions are also starting to include cognitive function as an outcome measure.
Keywords: Type 2 diabetes cognition dementia vascular disease glucocorticoids
Accepted for publication October 28, 2008.
![]()
CiteULike
Connotea
Del.icio.us What's this?
Related articles in BMB:
- Editor's Choice
BMB 2008 88: 1-6.[Extract] [FREE Full Text]
This article has been cited by other articles:
![]() |
S. Craft The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia: Two Roads Converged Arch Neurol, March 1, 2009; 66(3): 300 - 305. [Abstract] [Full Text] [PDF] |
||||
